Nephrol Dial Transplant (2001) 16: 1108-1111
© 2001 European Renal Association-European Dialysis and Transplant Association
Editorial Comment
ß2-Microglobulin and bone cell metabolism
1 Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts, 2 Department of Medicine, Evanston-Northwestern Healthcare, Northwestern University Medical School, Evanston, Illinois, USA
Keywords: bone; dialysis-related amyloidosis; end-stage renal disease; interleukin-1ß; interleukin-6; ß2-microglobulin; osteoblast proliferation
Introduction
Dialysis-related amyloidosis (DRA), also referred to as ß2-microglobulin (ß2M) amyloidosis, is a major cause of skeletal morbidity in patients with end-stage renal disease. The DRA syndrome results in a progressive destructive periarticular osteoarthropathy. The pathological lesions of DRA consist of cystic lesions and localized areas of ß2M-amyloid deposition. Approximately 70% of adult patients who undergo dialysis for more than 10 years develop radiographic evidence and/or symptomatic pathology associated with ß2M-amyloid deposition [1]. With advances in the treatment of the cardiac and cerebrovascular complications associated with end-stage renal disease, it is anticipated that the life expectancy of dialysis patients will continue to increase. Thus, morbidity from bone disease in general and DRA in particular will become more prevalent. Over the past decade numerous hypotheses have been put forward in an attempt to explain how ß2M might affect bone cell metabolism and play a
Effect of ß2M on bone
Is ß2M a growth factor?
Summary
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. P. Gobin, P. Biesta, and P. J. Van den Elsen Regulation of human beta 2-microglobulin transactivation in hematopoietic cells Blood, April 15, 2003; 101(8): 3058 - 3064. [Abstract] [Full Text] [PDF]
|
|